Patient P-01603

Synthetic patientNBL-101 · Day 109 · 55–64 · M · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

85%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 41 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 54 SC-12 recommended — Supportive Compound SC-12
Day 55 Patient accepted — Started SC-12 in the companion
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 61 GI symptom burden −12% vs expected — Supportive Compound SC-12
Day 67 Tolerance state changed — Unstable → Improving
Day 69 GI symptom burden −23% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 41.

Primary contributors, last 14 days

GI instability+16
Toxicity+10
Inflammatory activity+5
Treatment adherence-3

What helped?

Supportive Compound SC-12Day 54
Result: symptom burden −12%
GI Support Protocol GI-04Day 60
Result: symptom burden −23%

LIFE OS recommendation

Monitoring Escalation ME-01

85%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 52 and rising
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 49
Autonomic recovery ↓45
- WearableResting HR 82 bpm
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 33/100
Drug metabolism and exposure ↑20
- BloodToxicity index 47

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.2 · butyrate capacity 33/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 45 ms
Sleep: 6.4 h
Steps: 8,714
Resting HR: 81 bpm

Daily log: GI score 52, nutritional resilience 53, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01556	58%	S14	GI-04	improved	44
P-01458	56%	S14	GI-04	improved	44
P-01570	56%	S14	SC-12	improved	46
P-01486	55%	S18	GI-04	improved	47
P-01539	55%	S14	GI-04	improved	43
P-01307	53%	S14	GI-04	improved	43
P-01365	53%	S14	SC-12	improved	49
P-01431	53%	S14	GI-04	improved	41
P-01494	53%	S14	GI-04	improved	42
P-01505	52%	S14	NP-02	improved	41
P-01611	52%	S14	GI-04	improved	44
P-01403	51%	S14	GI-04	improved	49